EUVIMEDEUVIMED entdecken
Open Access

ZPY-CpG-Ch, a broad coverage vaccine against Streptococcus pneumoniae

Teerawit Audshasai iD, Stavros Panagiotou iD, Lisa Crossman iD, Rong Xu iD, Lynn Verheijen iD, Chrispin Chaguza iD, Marie O'Brien iD, Aras Kadioglu iD

Science Advances · 07.08.2026 · 12 (32)

DOI: 10.1126/sciadv.aee7981 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 07.08.2026. Verfasst von Teerawit Audshasai und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Infection Microbiology & Immunology, Institute of Infection, Veterinary & Ecological Sciences, University of Liverpool, The Ro…. Hauptthemen laut MEDLINE: Streptococcus pneumoniae, Pneumococcal Vaccines, Pneumococcal Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Wellcome Trust, Wellcome, Meningitis Now.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Existing licensed pneumococcal vaccines, including Prevnar-13 and its higher-valency successors, have played a major role in reducing invasive pneumococcal disease worldwide. However, their effectiveness is increasingly threatened by the rise of multidrug-resistant strains and the shift in circulating serotypes toward those not targeted by current vaccines—a trend known as serotype replacement. These evolving challenges underscore the urgent need for next-generation vaccines with broader, serotype-independent protection—long considered the holy grail of pneumococcal vaccine development. Here, we report the discovery and preclinical evaluation of ZPY-CpG-Ch, a broad-coverage protein-based pneumococcal vaccine formulation. We assessed the protective efficacy and immunogenicity of ZPY-CpG-Ch in translational murine models, using both adult and neonatal mice, and tested various adjuvants, protein combinations, and doses, followed by challenge experiments with both vaccine- and non–vaccine-covered serotypes. Prevnar-13 was included as a benchmark. While Prevnar-13 ® demonstrated robust efficacy, our results show that ZPY-CpG-Ch achieves greater cross-serotype protection. We attribute this enhanced efficacy primarily to T H 17 (T helper 7)–biased immune responses. Together, these findings highlight the promise of genome-guided, protein-based vaccines in overcoming the limitations of current serotype-based approaches and represent a meaningful step toward a truly universal pneumococcal vaccine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Streptococcus pneumoniaePneumococcal VaccinesPneumococcal InfectionsAnimalsMiceSerogroupAntibodies, BacterialFemaleProtein Subunit Vaccines

Substanzen

Pneumococcal VaccinesAntibodies, BacterialProtein Subunit Vaccines

Autor:innen und Institutionen

  • Department of Clinical Infection Microbiology & Immunology, Institute of Infection, Veterinary & Ecological Sciences, University of Liverpool, The Ronald Ross Building, 8 West Derby St., Liverpool L69 7BE, UK.
  • Department of Microbiology, Faculty of Pharmacy, Mahidol University, 447, Thanon Si Ayutthaya, Khwaeng Thung Phaya Thai, Khet Ratchathewi, Bangkok 10400, Thailand.
  • SequenceAnalysis.co.uk, Norwich Research Park, Norwich NR4 7UG, UK.
  • School of Biological Sciences, University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, UK.
  • Host-Microbe Interactions Dept. at St Jude Children's Research Hospital, Danny Thomas Place, Memphis, TN 38105, USA.

ORCID-Profile: Teerawit Audshasai, Stavros Panagiotou, Lisa Crossman, Rong Xu, Lynn Verheijen, Chrispin Chaguza, Marie O'Brien, Aras Kadioglu

Förderung

  • Wellcome Trust
  • Wellcome
  • Meningitis Now
  • Medical Research Council
  • UK Medical Research Council
  • Liverpool-Mahidol

Zitieren

APA

Audshasai, T., Panagiotou, S., Crossman, L., Xu, R., Verheijen, L., Chaguza, C., O'Brien, M., & Kadioglu, A. (2026). ZPY-CpG-Ch, a broad coverage vaccine against Streptococcus pneumoniae. Science Advances, 12(32). https://doi.org/10.1126/sciadv.aee7981

Vancouver

Audshasai T, Panagiotou S, Crossman L, Xu R, Verheijen L, Chaguza C, et al. ZPY-CpG-Ch, a broad coverage vaccine against Streptococcus pneumoniae. Science Advances. 2026;12(32). doi:10.1126/sciadv.aee7981

BibTeX
@article{Audshasai2026,
  author = {Audshasai, Teerawit and Panagiotou, Stavros and Crossman, Lisa and Xu, Rong and Verheijen, Lynn and Chaguza, Chrispin and O'Brien, Marie and Kadioglu, Aras},
  title = {ZPY-CpG-Ch, a broad coverage vaccine against Streptococcus pneumoniae},
  journal = {Science Advances},
  year = {2026},
  volume = {12},
  number = {32},
  doi = {10.1126/sciadv.aee7981}
}
Kostenlos starten →